RAPT Therapeutics Inc

RAPT Therapeutics — Investor Presentation (January 2023)

28 slides from RAPT Therapeutics's investor presentation, Jan 9, 2023

  1. Slide 1: Transforming the Treatment of Inflammation and Cancer

    Exhibit 99.1 Transforming the Treatment of Inflammation and Cancer January 2023 Corporate Presentation

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the Company, we, or us ) research and clinical development plans;

  3. Slide 3: Oral Drugs Targeting Critical Immune Drivers of Disease

    Oral Drugs Targeting Critical Immune Drivers of Disease RPT193 (Inflammation): § Oral agent targeting inflammatory Th2 cells § Phase 1b in AD: efficacy on all key exploratory endpoints with excellent safety and tolerability Ø Proprietary discovery engine § Phase 2b in AD ongoing, data expected Q4 20

  4. Slide 4: Proprietary Drug Discovery and Development Engine

    Proprietary Drug Discovery and Development Engine § Drug discovery Rapid § Clinical development R § Interrogating clinically-relevant big datasets Analytics to identify targets and biomarkers A § Driven by data to improve chances Patient selection of clinical success P § Critical immune drivers of c

  5. Slide 5: RPT193: CCR4 Antagonist for Inflammatory Diseases

    RPT193: CCR4 Antagonist for Inflammatory Diseases

  6. Slide 6: RPT193: Oral Th2 Inhibitor for Inflammatory Diseases

    RPT193: Oral Th2 Inhibitor for Inflammatory Diseases § Highly potent and selective once-daily oral CCR4 AD Lesional Skin antagonist designed to safely reduce Th2-inflammation in a broad range of allergic disorders § Clear benefit on signs and symptoms in Phase 1b in moderate-to-severe atopic dermati

  7. Slide 7: RPT193 Targets Th2 Cells: Key Drivers of Inflammation

    RPT193 Targets Th2 Cells: Key Drivers of Inflammation in Atopic Dermatitis, Asthma and Other Diseases Allergen, Microbes Epithelial Barrier Surface CCL17 RPT193 is a potent and selective oral CCL22 CCR4 antagonist that specifically inhibits CCR4 Th2 cell migration and activation Signaling via CCR4 r

  8. Slide 8: Phase 1b Trial Explored RPT193 Activity in Moderate-to-Severe Atopic Dermatitis

    Phase 1b Trial Explored RPT193 Activity in Patients with Moderate-to-Severe Atopic Dermatitis Screening Treatment Follow-up (Up to 35 days) (28 days) (14 days) • ≥12-month history of AD • 18-65 years of age RPT193 400 mg once daily Obtain (inclusive) 2 Informed • BMI ≥18 and <40 kg/m • BSA ≥10% Cons

  9. Slide 9: Phase 1b Baseline Demographics and Disease Characteristics

    Phase 1b Baseline Demographics and Disease Characteristics Placebo RPT193 N 10 21 Age, Mean (Range) 35.8 (22-64) 41.0 (19-63) Female, n (%) 4 (40.0%) 12 (57.1%) Baseline Characteristics EASI, Mean (Range) 21.07 (13.6-45.5) 18.49 (12-30) BSA, Mean (Range) 24.5 (10-61) 23.3 (11-55) vIGA 3, n (%) 8 (80

  10. Slide 10: RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29

    RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29 with Further Improvement at Day 43 % Improvement in EASI Proportion of EASI-50 Treatment Treatment Follow-up Follow-up 60% 70% 60% 50% 50% 40% 40% 41.9% * 43.6% 30% * 19.3% 30% 32.9% 20% 20% 10% 10% 0% 0% Day 1 Day 8 Day 15 Day 29 Day

  11. Slide 11: RPT193 Differentiated from Placebo on EASI-75 and vIGA 0/1 at Day 43

    RPT193 Differentiated from Placebo on EASI-75, 90 and vIGA 0/1 at Day 43 EASI ≥ 12 ITT EASI ≥ 16 Subgroup 70% 70% ** * 63.6% 61.9% 60% 60% 50% 50% 40% 40% 36.4% 28.6% 30% 30% 27.3% 20% 20% 20% 14.3% 9.5% 9.1% 10% 10% 0% 0% 0% 0% 0% 0% 0% 0% 0% EASI-50 EASI-75 EASI-90 vIGA 0/1 EASI-50 EASI-75 EASI-90

  12. Slide 12: RPT193 Demonstrated Significant Improvement in AD-Associated Gene Signatures

    RPT193 Demonstrated Significant Improvement in AD-Associated Gene Signatures in the Skin Mean % Improvement in MADAD Transcriptome RPT193 PbO NL Day1 Day29 NL Day1 Day29 *** 52% 40 ***(p<0.001) MADAD: Meta-Analysis Derived 20 Atopic Dermatitis score -4% 0 PbO RPT193 Changes in the Lesional AD Transc

  13. Slide 13: RPT193 Demonstrated Improvement in Itch and Sleep

    RPT193 Demonstrated Improvement in Itch and Sleep † Proportion of NRS-4 % Change in Patient Oriented SCORAD (Sleep Loss + Pruritus) 50% Day 1 Day 8 Day 15 Day 29 Day 43 45.0% 80% 40% 60% 40% 30% 20% 22.2% 0% 20% -20% -40% * 10% -60% 0% -80% PbO RPT193 PbO RPT193 † *p < 0.05 At least a 4-point improv

  14. Slide 14: RPT193 6-Week Efficacy vs. Other Drugs at 12-16 Weeks

    RPT193 6-Week Efficacy vs. Other Drugs at 12-16 Weeks* 0 20 40 60 100 % EASI improvement RPT193 EASI-50 RPT193 EASI-75 RPT193 vIGA 0 or 1 RPT193 All data shown are placebo-adjusted RPT193 Dupilumab Lebrikizumab Tralokinumab Abrocitinib Baricitinib Etrasimod Upadicitinib 400 mg Ph3 Ph2 Ph3 Ph3 Ph3 Ph

  15. Slide 15: RPT193 Phase 1b Safety

    RPT193 Phase 1b Safety § No SAEs reported § All AEs reported were mild or moderate in intensity § No clinically significant safety laboratory abnormalities observed § Overall safety profile suggests a well-tolerated oral drug that should not require laboratory safety monitoring 15

  16. Slide 16: Ongoing Dose-Finding Phase 2b Monotherapy Trial in Atopic Dermatitis

    Ongoing Dose-Finding Phase 2b Monotherapy Trial in Patients with Moderate-to-Severe Atopic Dermatitis Screening Treatment Follow-up (Up to 5 weeks) (16 weeks) (up to 8 weeks) RPT193 400 mg once daily • ≥12-month history of AD RPT193 200 mg once daily Obtain • 18-75 years of age BMI ≥18 Informed • BS

  17. Slide 17: Proposed Phase 2a Asthma Trial Design

    Proposed Phase 2a Asthma Trial Design Treatment Follow-up Screening (14 weeks) (6 weeks) (Up to 6 weeks) RPT193 400 mg once daily § Run-in with § Moderate- standardized Obtain to-severe inhaled Informed Type 2 therapy Consent Placebo asthmatics (ICS+LABA and SABA) Evaluation as Add-on Tapering of In

  18. Slide 18: RPT193 Commercial Vision: Building a Global Blockbuster

    RPT193 Commercial Vision: Building a Global Blockbuster Simple, once-daily oral providing symptom relief and lesion reduction Value Statement Favorable tolerability and safety from exquisite selectivity Positioning As the first-choice systemic therapy RPT193 Injectable Biologics Oral JAKs Topical JA

  19. Slide 19: Potential "Pipeline in a Product"

    Potential “Pipeline in a Product” Dermatology Respiratory Allergy Atopic Dermatitis Asthma Chronic Rhinosinusitis Chronic Urticaria Allergic Rhinitis COPD (Th2 high) Alopecia Areata IPF Eosinophilic Esophagitis Prurigo Nodularis Bullous Pemphigoid Th2-Driven Inflammatory Diseases 19

  20. Slide 20: RPT193 Program Summary

    RPT193 Program Summary § Oral selective Th2 inhibitor with clear benefit on signs and symptoms in AD § Well tolerated with favorable safety § Profile supports competitive positioning ahead of injectables and oral JAKs § Massive commercial opportunity in AD, asthma and other Th2 indications § 16-week

  21. Slide 21: FLX475: CCR4 Antagonist for Oncology

    FLX475: CCR4 Antagonist for Oncology

  22. Slide 22: Treg Are Key Targets in the Tumor Microenvironment

    T Are Key Targets in the Tumor Microenvironment (TME) reg Cancer Types CD8 § Correlate with poor prognosis across most cancers T reg § Mechanism for immune evasion by viruses and tumors § Barrier to checkpoint inhibitor efficacy § Challenge: selective inhibition of T in the TME reg – Depleting antib

  23. Slide 23: FLX475: Tumor Specific Treg Inhibitor in Phase 2

    FLX475: Tumor Specific T Inhibitor in Phase 2 reg T -Suppressed Tumor reg Microenvironment § Chemically distinct potent and selective CCR4 small molecule antagonist § Selectively blocks tumor T while sparing reg normal tissues and beneficial cells § Potential for superior safety and efficacy FLX475

  24. Slide 24: Identification and Characterization of Charged Tumors

    Identification and Characterization of Charged Tumors + + Gastric EBV NPC EBV + Cervical HPV § “Charged” tumors: high CCR4 HNSCC TNBC ligands, T and CD8 T cells reg NHL NSCLC Sq. § Potential for both monotherapy T reg NSCLC Ad. and combination activity § Include cancers with high unmet need and larg

  25. Slide 25: Encouraging Monotherapy and Combination Efficacy

    Encouraging Monotherapy and Combination Efficacy EBV+ NK/T Lymphoma (Monotherapy) CPI-Naïve NSCLC (Combo) uPR Time Since Start of Treatment, Days cPR cPR § 4 of 6 responses to FLX475 monotherapy cPR including 2 confirmed durable CMR cPR ORR Comparison in PD-L1+* NSCLC § Design: Open-label Phase 2, S

  26. Slide 26: FLX475 Program Summary

    FLX475 Program Summary § Highly selective tumor T inhibitor differentiated from biologics reg § Encouraging early efficacy as monotherapy and in combination with pembrolizumab § Favorable safety and convenient oral dosing support broad combinability § Enrolling Stage 2 expansions in 3 indications in

  27. Slide 27: Key Takeaways and Upcoming Milestones

    Key Takeaways and Upcoming Milestones § RPT193: safe oral agent designed for a broad range of inflammatory diseases, in a definitive Phase 2b study in AD § FLX475: highly selective tumor T inhibitor in multiple Phase 2 reg expansions as monotherapy and in combination with pembrolizumab § Planned Key

  28. Slide 28: Thank You

    Thank You

RAPT Therapeutics — Investor Presentation (January 2023) on 6ix